EGFR and breast cancer: LOX inhibitors have been the subject of extensive preclinical research.348 Among these, β-aminopropionitrile (BAPN) and the aminomethyl thiophene-based inhibitor CCT365623 effectively suppress the migration and invasion of breast cancer cells.349,350 Furthermore, PAT-1251/GB2064, a highly selective LOXL2 inhibitor, has shown promise in reducing collagen accumulation and inhibiting tumor growth in preclinical settings.351 CCT365623 disrupts HTRA1 multimerization, activates TGF-β1 signaling, suppresses MATN2 expression, inhibits EGFR surface retention, and attenuates EGFR signaling.